One of the largest, broadest and deepest pipelines of any technology-enabled drug discovery company.

Every program at Recursion is a product of our Recursion OS. With every new discovery, our platform gets smarter, leading to pipeline growth.

Our programs target diseases spanning several therapeutic areas where:


1. the cause of the disease is well-defined

2. there is high unmet need, there are no approved therapies, or there are significant shortcomings with existing treatment paradigms

Expanded Access Policy
Therapeutic Area
Disease Indication
Late Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Oncology

Familial Adenomatous Polyposis

AXIN1/APC Mutant Cancers with an Initial Focus in HCC and Ovarian

KRAS/STK11-Driven Checkpoint Resistance

MYC-Driven Oncology

Cancer Immunotherapy Target Alpha

Cancer Immunotherapy Target Beta

HRD-Negative Ovarian Cancer Target Gamma

Rare & Other

Cerebral Cavernous Malformation

Neurofibromatosis Type 2

Clostridium difficile Colitis

Partnership Programs

More than a dozen early discovery and research programs in oncology, neuroscience, inflammation & immunology, and rare disease.

Therapeutic Area - Oncology
Phase 2

Familial Adenomatous Polyposis

Phase 1

AXIN1/APC Mutant Cancers with an Initial Focus in HCC and Ovarian

Preclinical

KRAS/STK11-Driven Checkpoint Resistance

Late Discovery

MYC-Driven Oncology

Cancer Immunotherapy Target Alpha

Cancer Immunotherapy Target Beta

HRD-Negative Ovarian Cancer Target Gamma

Therapeutic Area - Rare & Other
Phase 2

Cerebral Cavernous Malformation

Neurofibromatosis Type 2

Phase 1

Clostridium difficile Colitis

Partnership Programs

Multiple Programs Advancing Simultaneously

More than a dozen early discovery and research programs in oncology, neuroscience, inflammation, and immunology, and rare disease.
Disease Indication
Early Discovery
Late Discovery
Preclinical
Phase 1
Phase 2

Neurofibromatosis Type 2

Familial Adenomatous Polyposis

Cerebral Cavernous Malformation

GM2 Gangliosidosis

AXIN1/APC Mutant Cancers with an Initial Focus in HCC and Ovarian

Clostridium difficile Colitis

KRAS/STK11-Driven Checkpoint Resistance

Charcot-Marie-Tooth Disease Type 2A

Batten Disease

Ovarian cancer

HRD-Negative Ovarian Cancer Target Gamma

Hepatocellular carcinoma

Cancer Immunotherapy Target Beta

Cancer Immunotherapy Target Alpha

MYC-Driven Oncology

Several dozen early discovery programs

Phase 2

Neurofibromatosis Type 2

Familial Adenomatous Polyposis

Cerebral Cavernous Malformation

Phase 1

GM2 Gangliosidosis

AXIN1/APC Mutant Cancers with an Initial Focus in HCC and Ovarian

Clostridium difficile Colitis

Preclinical

KRAS/STK11-Driven Checkpoint Resistance

Late Discovery

Charcot-Marie-Tooth Disease Type 2A

Batten Disease

Ovarian cancer

HRD-Negative Ovarian Cancer Target Gamma

Hepatocellular carcinoma

Cancer Immunotherapy Target Beta

Cancer Immunotherapy Target Alpha

MYC-Driven Oncology

Early Discovery

Several dozen early discovery programs

Phase 2

Cerebral Cavernous Malformation

Neurofibromatosis Type 2

Familial Adenomatous Polyposis

Phase 1

GM2 Gangliosidosis

Clostridium difficile Colitis

Preclinical

KRAS/STK11-driven checkpoint resistance

Late Discovery

MYC-driven oncology

Cancer immunotherapy target alpha

Cancer Immunotherapy Target Beta

Hepatocellular carcinoma

HRD-negative ovarian cancer target gamma

Ovarian cancer

Charcot-Marie-Tooth Disease Type 2A

Batten Disease

Early Discovery

Several dozen early discovery programs

Phase 2
Phase 3
Commercial
Disease Model
Early Discovery
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial

Neurofibromatosis Type 2

Cerebral Cavernous Malformation

GM2 Gangliosidosis

Solid Tumors

Dilated Cardiomyopathy

Clostridium difficile Colitis

Neuroinflammation

Batten Disease

Charcot-Marie-Tooth Disease

Pulmonary Arterial Hypertension

Lung Disease

Senescence

Vascular Disease

+ 18 early
discovery programs

Oncology 1

Oncology 2

Phase 1

Neurofibromatosis Type 2

Cerebral Cavernous Malformation

GM2 Gangliosidosis

*Undisclosed indication

Disease Indication
Early Discovery
Late Discovery
Preclinical
Phase 1
Phase 2
Commercial
Cerebral Cavernous Malformation
Neurofibromatosis Type 2
Familial Adenomatous Polyposis
GM2 Gangliosidosis
Clostridium difficile Colitis
KRAS/STK11-driven checkpoint resistance
MYC-driven oncology
Cancer immunotherapy target alpha
Cancer immunotherapy target beta
Hepatocellular carcinoma
HRD-negative ovarian cancer target gamma
Ovarian cancer
Charcot-Marie-Tooth Disease Type 2A
Batten Disease
Several dozen early discovery programs
18

Early Discovery

Metabolic Disorders
Tumor Suppression
Cancers
Mitochondrial Diseases
Lysosomal Storage Disorders
Nervous System Disorders
Neurodevelopment Disorders
Neurodegenerative Disorders
Inflammation

4

Discovery

Lung Disease
Senescence
Vascular Dysplasia
Tumor Suppression

6

Preclinical

Dialated Cardiomyophathy
Clostridium Difficile Colitis
Amitrophic Lateral Sclerosis
Batten Disease
Charcot-Marie-Tooth Disease
Pulmonary Arterial Hypertension

3

Phase 1

Neurofibromatosis Type 2
Cerebral Cavernous Malformation
*Undisclosed indication

Welcome to the era of industrialized drug discovery.

Proud founding member of BioHive, the fastest growing life sciences community in the nation

Get In Touch

41 S Rio Grande Street
Salt Lake City, UT 84101
phone: (385) 269-0203
fax: (801) 821-2872
info@recursion.com
Investor Relations

Policies

Website Terms of Use
Privacy Policy
Vendor Expectations Manual

Connect

LinkedIn
Twitter
Youtube